Overall survival of 123 patients with CB lymphoma treated by the COP-BLAM/IMVP-16 regimen (BMFT trial5 ) (patients at risk at 1/2/3/4 years). CB lymphoma subgroups (Kiel classification): ———, multilobated n = 28 (20/17/14/5); - - - -, polymorphic n = 74 (47/37/26/11); ⋅⋅⋅⋅, monomorphic n = 21 (16/12/10/2); P = .48.